Amarin Corp Plc (AMRN)

[chas1232123]

I just noticed Dr. John Kastelein, who co-authored the NEJM editorial that included a mild mention of mineral oil, and who was quoted in the Forbes follow-up article as recommending Vascepa, and who co-authored the uptodate recommendation to not take V for now citing mineral oil, was named to MTNB's new scientific advisory board in December. He also led two trials that had LDL-C increases bigger than RI's.


MTNB has an unpublished scientific poster that compares plasma EPA levels for their drug MAT9001 against Vascepa. MAT9001 is a blend with EPA and DPA. Their tiny trial (about 40 subjects for a few weeks) several years ago showed much higher levels of plasma EPA compared to Vascepa. Several red flags, including they gave the entire dose in the morning after an extremely low-fat breakfast. V needs some fat for good absorption, and is labeled with food 2g every 12 hours. They suppressed V absorption by violating directions. BTW, their trial was unblinded, conducted in Canada, and the subjects resided in their facility throughout the trial. They reported Vascepa plasma EPA levels far below levels measured in large clinical trials (Anchor, Marine and RI).


Does anyone know what's up with the uptodate website re Vascepa?